Weitzner MA. Psychosocial and neuropsychiatric aspects of patients with primary brain tumours. Cancer Invest1999; 17: 285–291.
2.
Leysen JE, Gommersen W, Eens A, De Chaffoy De Courcelles D, Stoof JC, Janssen PAJ. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther1988; 247: 661–670.
3.
De Oliveira IR, Miranda-Scippa AMA, de Sena EP. Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety. J Clin Pharm Ther1996; 21: 349–358.
4.
Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American Trials. J Clin Psychiatry1997; 58: 538–546.
5.
De Deyn PP, Katz IR. Control of aggression and agitation in patients with dementia: efficacy and safety of risperidone. Int J Geriatr Psychiatry2000; 15(S1): S14–S23.
6.
Lodge P. Risperidone in the management of agitation in HIV dementia. Palliat Med1998; 12: 206–207.
7.
Nyberg S, Farde L, Eriksson L, Halldin C, Eriksson B. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. Psychopharmacology1993; 110: 265–272.
8.
Demczar D, Levin GM. Use of atypical antipsychotics on an as-needed basis. J Pharm Technol1996; 12: 145–148.
Green MF, Marshall BD Jr, Wirshing WC. Does risperidone improve verbal working memory in treatment-resistant schizophrenia?Am J Psychiatry1997; 154: 799–804.
11.
Wasserman TW. Risperidone in patients with developmental disabilities (Abstract). 149th Annual Meeting of the American Psychiatric Association, New York, 4–9 May 1996; NR367: 167.
12.
Passik SD, Cooper M. Complicated delirium in a cancer patient successfully treated with olanzapine. J Pain Symptom Manage1999; 17: 219–223.
